Major studies, compressed into the finding, the clinical caveat, and the question worth carrying into practice.
In a pragmatic, open-label trial of 513,358 adults, RSV-related respiratory hospitalization was 0.16 vs 0.55 events per 1,000 person-years. Estimated effectiveness: 70.3% (95% CI 49.7–83.2).
The absolute reduction was 0.39 events per 1,000 person-years. Consider patient risk, local eligibility and access.
Among 142,250 participants aged 50–77, stage III–IV incidence across 12 prespecified cancers was not significantly lower after three rounds: incidence rate ratio 1.03 (95% CI 0.92–1.14), P=0.63.
The primary late-stage cancer endpoint was neutral. Better detection alone does not prove better patient outcomes.
In 709 children with newly diagnosed high-risk B-cell ALL, estimated 4-year EFS was 83.0% vs 70.3%; HR 0.51 (95% CI 0.35–0.73). Interim analysis; median follow-up 2.9 years.
Only two selected chemotherapy cycles were replaced. EFS improved, but neurotoxic events were more frequent (12.0% vs 3.2%).
Two placebo-controlled phase 3 trials enrolled 168 and 105 people. At 12 weeks, MWT sleep-latency change was +14.3 to +19.8 minutes with oveporexton vs −0.4 to −0.8 with placebo.
Wakefulness and cataplexy improved. Urinary frequency and transient insomnia were common; long-term safety remains uncertain.
Study summaries reproduce the editorial content of Issue 03, November 2026. Clinicians should review the primary paper and current guidance before changing practice.
